Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease

doi:10.5527/wjn.v12.i5.132

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2579)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1535

Figures (1-6)

113

Tables (1-3)

116

Sum=1812

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

268

Sum=350

Publishing Process of This Article

Item

Count

Browse

Download

238

Sum=318

Dec 25, 2023 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Nephrol. Dec 25, 2023; 12(5): 132-146
Published online Dec 25, 2023. doi: 10.5527/wjn.v12.i5.132

Table 2 Sensitivity analysis of negative controls after inverse probability of treatment weighting in an on-treatment analysis

	Incident rate of rivaroxaban 15 mg 100 PY (95%CI)	Incident rate of warfarin 100 PY (95%CI)	HR (95%CI)¹	P value
Diabetes complications	1.1 (0.2-2.0)	1.1 (0.6-1.5)	1.02 (0.40-2.60)	0.96
	Incident rate of rivaroxaban 20 mg 100 PY (95%CI)	Incident rate of warfarin 100 PY (95%CI)	HR (95%CI)¹	P value
Diabetes complications	1.5 (0.6-2.4)	1.0 (0.6-1.5)	1.48 (0.72-3.06)	0.29
	Incident rate of apixaban 2.5 mg 100 PY (95%CI)	Incident rate of warfarin 100 PY (95%CI)	HR (95%CI)¹	P value
Diabetes complications	0.8 (0.3-1.3)	1.2 (0.8-1.7)	0.66 (0.31-1.41)	0.28
	Incident rate of apixaban 5.0 mg 100 PY (95%CI)	Incident rate of warfarin 100 PY (95%CI)	HR (95%CI)	P value
Diabetes complications	0.7 (0.2-1.1)	1.4 (0.9-1.9)	0.49 (0.24-1.02)	0.06

A significant value is for P < 0.05 vs warfarin.

¹For the negative control, we assessed the risk of diabetic complications (ICD-9: 250.1-250.9, 357.2, and 366.41; ICD-10: E10-E14 excluding E10.9, E11.9, E12.9, E13.0, and E14.9).

CI: Confidence interval; HR: Hazard ratio; PY: Person-years.

Citation: Perreault S, Boivin Proulx LA, Lenglet A, Massy ZA, Dorais M. Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease. World J Nephrol 2023; 12(5): 132-146
URL: https://www.wjgnet.com/2220-6124/full/v12/i5/132.htm
DOI: https://dx.doi.org/10.5527/wjn.v12.i5.132